J Korean Med Assoc.  2008 Apr;51(4):371-376. 10.5124/jkma.2008.51.4.371.

DPP-4 Inhibitors and the Relations between Rosiglitazone and the Risk of Myocardial Infarction

• Lee HW

• KMID: 2185748
• DOI: http://doi.org/10.5124/jkma.2008.51.4.371

Abstract

If the type 2 diabetes is left untreated, it can eventually be lead to vascular complications, including nephropathy, retinopathy, neuropathy, coronary heart disease, and CVA. The current antidiabetic drugs are all generally effective in the medium term, not effective eventually. In addition, they may also be associated with an increased risk of hypoglycemia, weight gain, and gastrointestinal intolerance. The dipeptidyl peptidase 4 (DPP-4) inhibitors control elevated blood glucose by increasing active glucagon- like peptide-1 (GLP-1), increasing insulin secretion and inhibiting glucagon secretion. The DPP-4 inhibitors, such as vildagliptin (Galvus) and sitagliptin (Januvia), have shown clinically significant HbA1c reductions up to 2 years of treatment and many potential advantages including a low risk of hypoglycemia, but no effect on body weight. They are used as monotherapy and also in combination with metformin or thiazolidinedione or sulfonylureas and are suitable for once-daily oral dosing to treat patients with the type 2 diabetes mellitus. The thiazolidinediones are agonists for peroxisome proliferator-activated receptor gamma (PPAR-gamma) and lowering blood glucose primarily by increasing insulin sensitivity in peripheral tissues. Rosiglitazone is widely used as monotherapy or in fixed dose combinations with either metformin or glimepiride to treat patients with the type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. Dr. Nissen assisted that rosiglitazone should be associated with a significant increase in the risk of myocardial infarction. This review focused on the clinical effect of DPP-4 inhibitors and the relations between rosiglitazone and the risk of myocardial infarction.

Keyword

DPP-4 inhibitor; Vildagliptin; Sitagliptin; Rosiglitazone; Myocardial infarction

MeSH Terms

Adamantane
Blood Glucose
Body Weight
Coronary Disease
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase 4
Glucagon
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin
Insulin Resistance
Metformin
Myocardial Infarction
Nitriles
PPAR gamma
Pyrazines
Pyrrolidines
Sitagliptin Phosphate
Sulfonylurea Compounds
Thiazolidinediones
Triazoles
Weight Gain
Adamantane
Blood Glucose
Dipeptidyl Peptidase 4
Glucagon
Hypoglycemic Agents
Insulin
Metformin
Nitriles
PPAR gamma
Pyrazines
Pyrrolidines
Sulfonylurea Compounds
Thiazolidinediones
Triazoles

Reference

1. Nathan DM, Buse JB, Davidson MB, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006. 29:1963–1972.

2. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003. 26:2929–2940.

3. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003. 17:161–171.

4. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PRO-active investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet. 2005. 366:1279–1289.

5. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med. 2007. 356:2457–2471.